Breaking New Ground in Alzheimer’s Treatment: A Deep Dive into Lilly’s Kisunla™ (Donanemab-azbt) FDA Approval
July 16, 2024
The recent FDA approval of Lilly’s Kisunla™ (donanemab-azbt) for early symptomatic Alzheimer’s disease marks a monumental breakthrough in combating this debilitating condition. As we celebrate this achievement, it’s crucial to explore its implications and highlight how our innovative humanized mouse models contribute to advancing Alzheimer’s research. Kisunla™ targets the amyloid plaques that accumulate in the […]
Research Impact: B-NDG Mice Used to Identify Lipid Transport Mechanism Driving T Cell Leukemogenesis
September 29, 2022
By John Charpentier, Ph.D. September 29, 2022 A recent study featuring Biocytogen mice identifies a non-vesicular lipid transport mechanism required for T cell leukemogenesis. Wenbing Zhong and colleagues at Jinan University in Guangzhou, China report that a lipid binding protein called ORP4L, which is expressed in adult T cell leukemia (ATL) cells but not normal […]
Research Impact: Custom Biocytogen mouse models used to identify critical mediator of inflammation-driven metastases
September 7, 2022
By John Charpentier, Ph.D. September 7, 2022 While metastases are ultimately responsible for the large majority of cancer deaths, most oncology drugs in development target primary tumors, and few specifically prevent metastasis. Although surgical resection of solid tumors is an effective early treatment intervention, the resulting inflammation can promote metastasis by increasing adhesion of circulating […]
